COMMUNIQUÉS West-GlobeNewswire

VTAK Announces Preliminary Second Quarter Record Revenue in Excess of $1 million
15/07/2026
Flyte Vision Jet Segment up 61% sequentially over Q1, 2026, contributing $767,000 MedTech segment up 27% over Q2 2025 FORT MILL, S.C., July 15, 2026 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (VTAK: NYSE/American), [...]
ENvue Medical Appoints Chairman of the Board and New Directors, Bringing Clinical, AI Governance and Capital Markets Expertise to Navigation Platform
15/07/2026
Zeev Rotstein, M.D. Named Chairman Following Four Decades in Health System Leadership, Including 12 Years as Director General of Sheba Medical Center Zvi Joseph and Lior Buchman Join Board, Bringing Amdocs AI Governance [...]
Rani Therapeutics Announces Positive Initial Phase 1a Data for RT-114 for the Treatment of Obesity, with Oral Bioavailability Exceeding Matched Subcutaneous Dosing
15/07/2026
RT-114 achieved systemic exposure greater than 150% relative to a matched 12mg subcutaneous dose of PG-102 No adverse events attributed to RaniPill Capsule; treatment-related adverse events were mild and consistent with [...]
Autonomix Medical Granted U.S. Patent for Overactive Bladder Diagnosis and Treatment Platform
15/07/2026
Newly Issued Patent Expands Company's Neural Sensing Technology Platform into Large Urology Market Affecting Approximately 37 Million Americans THE WOODLANDS, TX, July 15, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc [...]
NOMAD Power Solutions Strengthens Subsidiary Executive Leadership
15/07/2026
Huda Almashhadany Joins Team as Chief of Product & VP of Operations, Company Names Brian Dockendorf as Director of Service Boca Raton, Fla., July 15, 2026 (GLOBE NEWSWIRE) -- NOMAD Power Solutions, Inc. (“NOMAD” or [...]
Slate Medicines Strengthens Board of Directors with Appointment of Mark W. Hahn
15/07/2026
RALEIGH, N.C., July 15, 2026 (GLOBE NEWSWIRE) -- Slate Medicines (Slate), a privately-held biotech company advancing next-generation therapeutics for migraine and other headache disorders, today announced the [...]
SBC Medical to Participate in the “Health, Wellness & Longevity” Virtual Conference Presented by Maxim Group LLC on Wednesday, July 22nd at 10:30 a.m. ET
15/07/2026
IRVINE, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a Medical Services Organization providing management support across a wide range [...]
UroGen Receives New U.S. Patent Allowance Expected to Provide Protection into July 2044 for ZUSDURI™ and UGN-103
15/07/2026
PRINCETON, N.J., July 15, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today [...]
MediciNova Announces Patient Enrollment Milestone Achieved in SEANOBI Study Expanded-Access-Program Evaluating MN‑166 (ibudilast) in ALS patients
15/07/2026
LA JOLLA, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875 [...]
NewcelX Granted Patent in Brazil for NCEL-101 in Type 1 Diabetes, Expanding Global IP Portfolio
15/07/2026
Brazil patent complements U.S. patent portfolio for NCEL-101, strengthening global position in the type 1 diabetes market ZURICH, July 15, 2026 (GLOBE NEWSWIRE) -- NewcelX Ltd. (“NewcelX”; Nasdaq: NCEL), a clinical- [...]
aTyr Pharma to Present Subgroup Analysis of Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis at WASOG 2026
15/07/2026
Patients with restrictive lung disease demonstrate clinically meaningful benefit in FVC and improvements in multiple PROs for 5.0 mg/kg efzofitimod compared to placebo. Company submitted protocol to FDA in June 2026 for [...]
Allogene Therapeutics Announces Journal of Clinical Oncology Publication of Phase 1 Results of ALLO-316 Highlighting First Durable Remissions Following Allogeneic CAR T for Treatment of Metastatic Solid Tumors
15/07/2026
ALLO-316 Achieved a 31% Confirmed Response Rate with the Recommended Phase 2 Regimen in Patients with Stage IV Renal Cell Carcinoma (RCC) with High CD70 Expression Single Dose of ALLO-316 Produced Durable Responses in [...]
Attovia Therapeutics Appoints John W. Smither to Board of Directors
15/07/2026
Mr. Smither brings extensive public company board and audit committee experience in the biotechnology sector SAN CARLOS, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- Attovia Therapeutics, Inc. (“Attovia” or the “Company [...]
The Coalition for Physician & APP Well-Being Launches “The Initiative Intelligence Guide” to Help Health Systems Better Evaluate Workforce, Retention, and Operational Initiatives
15/07/2026
The Coalition and American Hospital Association, AdventHealth, Atalan, and Providence’s Well Being Trust collaborate on practical framework for healthcare initiative evaluation ALTAMONTE SPRINGS, Fla., July 15, 2026 ( [...]
Nxera Pharma Webinar for Financial Results Presentation - 2Q2026
15/07/2026
Tokyo, Japan and Cambridge and London, UK, 15 July 2026 – Nxera Pharma Co. Ltd (“Nxera”; TSE 4565) will announce its earnings results and present operational highlights for 2Q 2026 on Friday, 7 August 2026. The Company [...]
Fractyl Health Reports Positive Randomized Data from REMAIN-1 Midpoint Cohort Demonstrating Durable Weight Maintenance One Year After GLP-1 Discontinuation
15/07/2026
Up to 84% of GLP-1 induced weight loss retained with Revita® versus 46% with sham at one year in patients receiving complete duodenal ablations Next anticipated Revita® milestones are topline six-month randomized data [...]
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2026
15/07/2026
Company Announcement Net sales of DARZALEX ® in the second quarter of 2026 totaled USD 4,207 million Genmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen Biotech, [...]
FDA grants Priority Review to Roche’s Gazyva/Gazyvaro for adults with primary membranous nephropathy
15/07/2026
Priority Review decision is based on phase III MAJESTY results, where Gazyva/Gazyvaro achieved significantly higher complete remission rates at two years compared to tacrolimus 1 If approved, Gazyva/Gazyvaro will be the [...]
Epoch Biotech Highlights New Preclinical Data for APOE Christchurch-Mimetic Antibody at AAIC 2026 Demonstrating Favorable PK/PD and Differentiated Biomarker Approach
15/07/2026
7C11 antibody builds on APOE Christchurch variant biology associated with resilience to Alzheimer’s disease, including effects on tau, amyloid and the brain vasculature New non-human primate data demonstrate favorable [...]

Pages